CTXR Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Citius Pharmaceuticals Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCTXR

Market Cap18.0M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Citius Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for LYMPHIR TM (Approved).

Pipeline

Asset	Indication	Modality	Stage	Public Note
LYMPHIR TM	n/a	n/a	Approved	Public pipeline row
LYMPHIR TM (denileukin diftitox-cxdl)	n/a	n/a	Phase 3	Public pipeline row
Phase 3 Trial	n/a	n/a	Pivotal	Public pipeline row
CITI-001	symptomatic relief of hemorrhoids	n/a	n/a	Public pipeline row
Hydrocortisone acetate and lidocaine hydrochloride	Hemorrhoids	n/a	Phase 2	Public pipeline row
E7777 9 mcg/kg	Persistent or Recurrent Cutaneous T-Cell Lymphoma	n/a	Phase 3	Public pipeline row
Monad 1	Hemorrhoids	n/a	Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT02689856	Phase 2	COMPLETED	211	2015-09
NCT01871727	Phase 3	COMPLETED	112	2021-12-06
NCT05348200	Phase 2	COMPLETED	304	2023-04-20

Scientific Context

literature_publication | Naïve CD4(+) T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.
literature_publication | Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.
literature_publication | Surveillance and Prevention of Vascular Catheter-Associated Infections.
literature_publication | CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
literature_publication | New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

Want the full CTXR research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.